Bupivacaine
Product Description
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
Categories
Specifications
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
More Products from QILU PHARMACEUTICAL CO., LTD. (26)
-
Product vedolizumab
Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics. -
Product Abaloparatide
Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b... -
Product Amphotericin B
Amphotericin B is a true single bilayer liposomal drug delivery system with amphotericin B intercalated within a liposomal membrane composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Liposomes are less than 100 nm in diameter. The liposomal encapsulation per... -
Product Aprepitant
Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5... -
Product atezolizumab
Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape. -
Product bevacizumab
Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape. -
Product daratumumab
Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment. -
Product denosumab
Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology. -
Product Ipratropium Bromide and Salbutamol
Ipratropium Bromide and Salbutamol is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta2-adrenergic agonist) delivered via the soft mist inhaler. It provides superior relief of bronchospasm compared to either agent alone in COPD patients with persistent symptoms despite reg... -
Product Leuprorelin (3M, 6M)
Leuprorelin uses lyophilized microsphere technology with leuprolide acetate embedded in biodegradable PLGA polymer microcapsules. The active drug is released in two phases—diffusion and bioerosion—enabling 3-month or 6-month dosing intervals. As a GnRH agonist, it induces pituitary desensitization to reduc... -
Product Nusinersen
Nusinersen is a modified antisense oligonucleotide (ASO) administered intrathecally. It binds to the ISS-N1 sequence in intron 7 of SMN2 pre-mRNA, promoting exon 7 inclusion and production of full-length functional SMN protein. Approved across all SMA phenotypes including Type I, II, III, and presymptomati... -
Product ocrelizumab
Ocrelizumab is an anti-CD20 mAb and the only approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS). With semiannual infusion and nearly 50% reduction in annualized relapse rate for RMS, it holds an unmatched position in neuroimmunology.